Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

PHASE3CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

June 30, 1997

Primary Completion Date

May 31, 1999

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBV-MPL vaccine

3-dose intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

Trial Locations (3)

GSK Clinical Trials Call Center, Wilrijk

GSK Clinical Trials Call Center, Toronto

GSK Clinical Trials Call Center, Gothenburg